Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Req...( WALTHAM Mass. June 30 /- In connectio...)

WALTHAM, Mass., June 30 /PRNewswire-FirstCall/ -- In connection with its proposed acquisition of London based, drugs of abuse testing company Concateno plc, announced on June 5 2009, Inverness Medical Innovations, Inc. (NYSE: IMA) has been requested by the UK Takeover Panel to remind Inverness shareholders through this announcement of their dealing disclosure obligations under Rule 8.3 of the UK Takeover Code.

Dealing disclosure requirements of the UK Takeover Code

Under the provisions of Rule 8.3 of the UK Takeover Code, if any person is, or becomes, "interested" (directly or indirectly) in one per cent (1%). or more of any class of "relevant securities" of either IMA or Concateno, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 p.m. (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the proposed acquisition becomes effective or the proposals lapse or are otherwise withdrawn, or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities", they will be deemed to be a single person for the purpose of Rule 8.3.

The numbers of "relevant securities" of Concateno and Inverness currently in issue can be found on the Takeover Panel's website at http://www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic exposure, wh
'/>"/>